Display Settings:

Format

Send to:

Choose Destination
    Surg Oncol Clin N Am. 2007 Jul;16(3):653-66, x.

    Cytoreductive surgery for peritoneal malignancies--development of standards of care for the community.

    Source

    Surgical Oncology, St. Agnes Hospital, 900 Caton Avenue, Baltimore, MD 21229, USA. jesusesquivel@yahoo.com

    Abstract

    Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) continue to play an increasing role in the management of peritoneal surface malignancies of gastrointestinal origin. The prognosis of patients and the responses to cytoreductive surgery and HIPEC depend on the histology, the degree of malignant transformation, the adequacy of the cytoreductive surgery, and the response to systemic therapy. Continuous interaction between medical and surgical oncologists is needed to identify the most appropriate patients for and the most efficient sequence of the available therapeutic modalities.

    PMID:
    17606199
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk